This project was completed by Intensity. Intensity joined Secretariat on February 1, 2023.
A number of generic drug companies sought FDA approval to market generic versions of a branded ADHD drug prior to the expiration of patents covering the branded drug. The generic drug companies filed Abbreviated New Drug Applications and Paragraph IV certifications asserting that patents covering the branded drug were invalid or not infringed. In response, the branded drug company filed claims of patent infringement against the generic drug companies.
Intensity provided an expert report, deposition testimony, and trial testimony relating to an evaluation of the commercial success of patents covering the branded drug. As part of addressing patent validity, the court considered the testimony of a Intensity expert on whether the patented invention had been a commercial success.
Intensity analyzed economic issues involving market definition, commercial performance, and long-felt need in the marketplace. Intensity performed economic analysis to evaluate sales and market share of the branded drug among competing drugs in the marketplace. In addition, we organized and processed complex data and presented its findings from the data analysis at trial.
Intensity analyzed a number of economic issues to inform on whether commercial performance of the branded drug was driven by the patents-in-suit or other economic factors. These issues included pricing, discounting, profitability, marketing, and other potential drivers of sales. Intensity also evaluated the economic impact of marketing materials that FDA had found to be false and misleading to consumers.
Secretariat’s Norman Harrison and Ben Boorer, together with Taylor Wessing attorneys Natasha Zahid and Mohammed Tartir, dive into the latest whistleblower issues and trends across the US, Europe, and the Middle East in their article, “When the Whistle Blows.”
Secretariat Experts Contribute to “2024 Annual Review of Antitrust Law Developments”
Secretariat team members Stuart Gurrea, Jéssica Dutra, Wei Tan, Pablo Varas, and Noah Case have contributed to “Chapter I — Restraints of Trade” in the recently published “2024 Annual Review of Antitrust Law Developments” from the ABA Antitrust Law Section. Michael Koenig contributed to “Chapter VIII — Civil Government Enforcement”.
Norman Harrison Named as 2025 Top Consultant by Consulting Magazine
Secretariat is proud to celebrate Norman Harrison’s recognition as a 2025 Top Consultant for Excellence in Regulation and Compliance by Consulting Magazine. This prestigious honor highlights his exceptional contributions to the consulting profession, particularly in helping clients navigate complex regulatory landscapes and ensuing investigations and disputes, as well as resolve compliance issues in highly regulated industries.